Cytori Cell Research Institute Co., Ltd. (3750) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Cytori Cell Research Institute Co., Ltd. (3750:JPX), powered by AI.

Current Price
¥791
P/E Ratio
-3.3
Market Cap
7.1B
Sector
Healthcare
What is the Cytori Cell Research Institute Co., Ltd. stock price forecast?

Cytori Cell Research Institute Co., Ltd. is currently trading at ¥791. View real-time AI analysis on Alpha Lenz.

What is Cytori Cell Research Institute Co., Ltd. insider trading activity?

View the latest insider trading data for Cytori Cell Research Institute Co., Ltd. on Alpha Lenz.

What is Cytori Cell Research Institute Co., Ltd.'s P/E ratio?

Cytori Cell Research Institute Co., Ltd.'s P/E ratio is -3.3.

Cytori Cell Research Institute Co., Ltd.

JPX · 3750
¥791-9(-1.13%)Market closedJPX regular session 09:00–15:00 JST
Ask about Cytori Cell Research Institute Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Cytori Cell Research Institute Co., Ltd. trades at a P/E of -3.3 (undervalued) with modest ROE of -125.1%.

Ask for details

Company Overview

Cytori Cell Research Institute Co., Ltd. is a biotechnology company primarily committed to the research and development of regenerative medicine. The company's primary focus lies in leveraging the potential of cellular therapies to address a variety of medical conditions. Cytori develops technologies that harness the regenerative capabilities of cells from adipose tissue, providing innovative solutions for a range of applications in healthcare. It impacts sectors such as orthopedics, cardiovascular medicine, and wound care, offering therapies with the potential to revolutionize treatment paradigms. The company also explores collaborations and partnerships to advance the development of cell therapies, ensuring comprehensive coverage from research to clinical application. With a significant presence in the biotechnology sector, Cytori is a pivotal player contributing to the evolution of medical treatments and enhancing the potential for recovery through cellular innovation.

CEOMr. Yoshihiro Hoshino
SectorHealthcare
IndustryBiotechnology
Employees10

Company Statistics

FY 2025

Profile

¥7,142,601,600Market Cap
¥122,204,000Revenue
0.00Shares Out
10Employees

Margins

-4.90%Gross
-598.32%EBITDA
-660.28%Operating
-1761.64%Pre-Tax
-1751.41%Net

Valuation

-3.34P/E
11.33P/B
58.45EV/Sales
-13.04EV/EBITDA
-7.18P/FCF

Growth (CAGR)

-54.94%Rev 3Yr
-36.47%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-45.76%ROA
-125.10%ROE
-44.28%ROIC

Financial Health

¥255,980,000Cash & Cash Equivalents
¥2,651,076,000Net Debt
461.05%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Cytori Cell Research Institute Co., Ltd. (ticker: 3750) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 10 employees. Market cap is $7.1B.

The current price is 791 with a P/E ratio of -3.34x and P/B of 11.33x.

ROE is -125.10% and operating margin is -660.28%. Annual revenue is $122M.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Cytori Cell Research Institute Co., Ltd. (3750) Stock Forecast 2026 ¥791 — Price, Financials & Analyst Targets | Alpha Lenz